Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 1/20 | 0.80 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.80 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.80 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.80 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.80 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 8/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.79 |
| ▸ | MAPT | P10636 | 5/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.79 |
| ▸ | TSHR | P16473 | 4/20 | 0.79 |
| ▸ | SHBG | P04278 | 4/20 | 0.79 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.79 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.79 |
| ▸ | PGR | P06401 | 4/20 | 0.79 |
| ▸ | AR | P10275 | 3/20 | 0.79 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.79 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12423994 | 1.00 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7614986 | 1.00 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5907025 | 1.00 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23784699 | 0.88 | LMNA (0.83) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12424000 | 0.88 | LMNA (0.83) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Progesterone SCHEMBL23568915 | 0.88 | CYP3A4 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Progesterone SCHEMBL12090497 | 0.88 | CYP3A4 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23784700 | 0.88 | LMNA (0.83) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23784747 | 0.88 | LMNA (0.83) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Progesterone SCHEMBL3932110 | 0.88 | CYP3A4 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104277089-A | Preparation method of androst-17 beta-carboxylic acid | HUNAN KEREY BIOTECHNOLOGY CO LTD | 2015-01-14 | — | — | CN | claimed |
| CN-101531698-A | Synthesis technology of finasteride | HALLOCHEM PHARMA CO LTD | 2009-09-16 | — | — | CN | claimed |
| CN-117946200-A | Eplerenone intermediate and preparation method thereof | 江苏联环药业股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-105017363-A | Synthesis methods of 4-androsten-3-one-17-beta-carboxylic acid and methyl 4-androsten-3-one-17-beta-carboxylate | HUNAN KERUI BIOTECHNOLOGY CO LTD | 2015-11-04 | — | — | CN | disclosed |
| CN-105017363-A | Synthesis methods of 4-androsten-3-one-17-beta-carboxylic acid and methyl 4-androsten-3-one-17-beta-carboxylate | HUNAN KERUI BIOTECHNOLOGY CO LTD | 2015-11-04 | — | — | CN | disclosed |
| CN-104277089-A | Preparation method of androst-17 beta-carboxylic acid | HUNAN KEREY BIOTECHNOLOGY CO LTD | 2015-01-14 | — | — | CN | disclosed |
| CN-101863954-B | Preparation method of N-tert-butyl-4-aza-5 alpha-androstane-3-ketone-17 beta-formamide | ZHEJIANG XIANJU YANGGUANG BIOPRODUCTS CO LTD | 2014-04-02 | — | — | CN | disclosed |
| CN-101863954-A | Preparation method of N-tert-butyl-4-aza-5 alpha-androstane-3-ketone-17 beta-formamide | ZHEJIANG XIANJU YANGGUANG BIOPRODUCTS CO LTD | 2010-10-20 | — | — | CN | disclosed |
| CN-101531698-A | Synthesis technology of finasteride | HALLOCHEM PHARMA CO LTD | 2009-09-16 | — | — | CN | disclosed |
| US-6432971-B2 | Method of prevention of prostatic carcinoma with 17β-N-monosubstituted-carbamoyl-4-aza-5α-androst-1-en-3-ones | MERCK & CO., INC. | 2002-08-13 | — | — | US | disclosed |
| US-20010049376-A1 | Method of prevention of prostatic carcinoma with 17beta-N-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO., INC. | 2001-12-06 | — | — | US | disclosed |
| EP-0271219-A1 | Topical pharmaceutical composition containing 17-beta-methoxycarbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one | MERCK & CO. INC. (US) | 1988-06-15 | — | — | EP | disclosed |
| EP-0155096-A2 | 17 Beta-Substituted-4-aza-5-alpha-androstenones and their use as 5-alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1985-09-18 | — | — | EP | disclosed |
| EP-0004949-B1 | 4-AZA-17-SUBSTITUTED-5-ALPHA-ANDROSTAN-3-ONE, THEIR A AND D HOMO ANALOGS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1983-09-21 | — | — | EP | disclosed |
| US-4377584-A | 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors | MERCK & CO., INC. (US) | 1983-03-22 | — | — | US | disclosed |
| US-4220775-A | Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors | MERCK & CO., INC. (US) | 1980-09-02 | — | — | US | disclosed |
| US-4191759-A | N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors | MERCK & CO., INC. (US) | 1980-03-04 | — | — | US | disclosed |
| US-4179453-A | Process for preparing 17β-carboxy-5-androsten-3-ones | MERCK & CO., INC. (US) | 1979-12-18 | — | — | US | disclosed |
| EP-0004949-A1 | 4-Aza-17-substituted-5-alpha-androstan-3-one, their A and D homo analogs, process for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1979-10-31 | — | — | EP | disclosed |
| US-4092413-A | Antiandrogens as platelet aggregation inhibitors | MERCK & CO., INC. (US) | 1978-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049376-A1 | Method of prevention of prostatic carcinoma with 17beta-N-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | NR5A1, CYP17A1, HSD17B7 | PSEN1 1899/4885PSEN2 3570/4885APH1B 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.